Stockreport

Cormedix Inc. Announces Preliminary First Quarter 2025 Results and Raises H1 2025 Net Sales Guidance

CorMedix Inc.  (CRMD) 
NASDAQ:AMEX Investor Relations: cormedix.com
PDF ? Q1 2025 Unaudited Net Revenue of $39.0 million ? ? Expected Q1 Adjusted EBITDA above $22.5 million ? ? Q1 2025 Cash and Cash Equivalents of Approximately $77 [Read more]